Keudell Morrison Wealth Management Acquires Shares of 5,033 Elevance Health, Inc. $ELV

Keudell Morrison Wealth Management acquired a new stake in Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 5,033 shares of the company’s stock, valued at approximately $1,764,000.

A number of other institutional investors have also recently bought and sold shares of the business. Sei Investments Co. grew its stake in shares of Elevance Health by 7.7% during the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock worth $63,666,000 after acquiring an additional 11,745 shares during the period. Glenview Trust co grew its stake in shares of Elevance Health by 41.5% during the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after acquiring an additional 475 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Elevance Health by 6.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after acquiring an additional 4,272 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Elevance Health by 5.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after acquiring an additional 2,012 shares during the period. Finally, Quantinno Capital Management LP grew its stake in shares of Elevance Health by 111.8% during the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after acquiring an additional 23,180 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

ELV has been the subject of several research reports. Mizuho increased their price target on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday. Guggenheim increased their price target on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Finally, Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a research note on Tuesday, February 3rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $396.16.

Elevance Health Stock Performance

Shares of ELV opened at $389.17 on Friday. The stock’s 50-day simple moving average is $331.71 and its 200 day simple moving average is $335.84. The stock has a market capitalization of $84.51 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 2.24 and a beta of 0.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts forecast that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.